Experienced in Ewing Sarcoma

Dr. Brock P. Whittenberger

Hematology Oncology
801 N 29th St, 
Billings, MT 
Experienced in Ewing Sarcoma
801 N 29th St, 
Billings, MT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brock Whittenberger is a Hematologist Oncology provider in Billings, Montana. Dr. Whittenberger is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Multiple Myeloma, Richter Syndrome, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

801 N 29th St, Billings, MT 59101

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

1 Total Publications

High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis.
High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis.
Journal: Physical biology
Published: February 07, 2012
Similar Doctors
Michael T. Kidd
Experienced in Ewing Sarcoma
Dr. Michael T. Kidd
Hematology Oncology | Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Michael T. Kidd
Hematology Oncology | Hematology | Oncology

Billings Clinic

801 N 29th St, 
Billings, MT 
 (0.1 miles away)
406-238-2500
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Kidd is a Hematologist Oncology specialist and a Hematologist in Billings, Montana. Dr. Kidd has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Neuroendocrine Tumor, Breast Cancer in Men, Paget Disease of the Breast, and Chronic Lymphocytic Leukemia (CLL).

Experienced in Ewing Sarcoma
Dr. David Christianson
Hematology Oncology
Experienced in Ewing Sarcoma
Dr. David Christianson
Hematology Oncology

Scl Health Montana

1315 Golden Valley Cir, 
Billings, MT 
 (4.0 miles away)
406-238-6290
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Christianson is a Hematologist Oncology provider in Billings, Montana. Dr. Christianson is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Breast Cancer in Men, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Whittenberger's expertise for a condition
ConditionClose
      View All 33 Advanced Conditions
      View All 112 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile